

Digestive Diseases Research Seminar



Presented by Yale School of Medicine's Department of Internal Medicine, Section of Digestive Diseases

"Acceleration of NASH in a mouse model by mutant PNPLA3"

Bubu A. Banini, MD, PhD

Clinical Fellow

Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Medical Center

Tuesday, October 2, 2018 TAC S-247 300 Cedar Street 5:00 - 6:00 pm

Host: Dr. Wajahat Mehal

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Target Audience: YSM faculty, fellows, and staff, and local GI physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. Needs assessment: Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) that can progress to fibrosis, cirrhosis and liver cancer requiring liver transplant. As the prevalence of NAFLD and NASH continues to trend upwards, many physicians and health care systems will face a substantial increase in the burden of disease associated with this entity over the next few decades. Development of animal models assist in understanding the complex pathogenesis of NASH, which can eventually be translated into targeted drug therapy. Objectives: Describe the prevalence and risk factors for NAFLD/NASH, including genetic risk factors. Describe the characteristics of an ideal preclinical model for the study of NAFLD/NASH. Understand the effect of mutant patatin-like phospholipase domain-containing protein 3 (PNPLA3) in a mouse model of NASH. Faculty Disclosures: X Zhang – None; W Mehal – None. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. This course will fulfill the licensure requirement set forth by the State of Connecticut.